Procedure characteristics
| Kyphoplasty (n = 191) | Vertebroplasty (n = 190) | P Value | |
|---|---|---|---|
| Surgery as randomized (No.) | 191 | 190 | |
| Physician type (m) (%) | .019 | ||
| Interventional radiologist | 117 (61.3) | 138 (72.6) | |
| Interventional neuroradiologist | 33 (17.3) | 27 (14.2) | |
| Orthopedic surgeon | 41 (21.5) | 23 (12.1) | |
| Neurosurgeon | 0 | 2 (1.1) | |
| Anesthesia (m) (%) | .086 | ||
| Local with conscious sedation | 125 (65.4) | 143 (75.3) | |
| General | 55 (28.8) | 37 (19.5) | |
| Other | 11 (5.8) | 10 (5.3) | |
| Hospitalization (m) (%) | .014 | ||
| Outpatient | 109 (57.1) | 132 (69.5) | |
| Inpatient | 82 (42.9) | 58 (30.5) | |
| Postural reduction performed (m) (%) | 154 (80.6) | 142 (75.1) | .217 |
| Procedure duration (min) (mean) (SD) | 40.0 (22.0) | 31.8 (19.3) | <.001 |
| Fluoroscopy duration (min) (mean) (SD) | 10.0 (6.3) | 8.5 (4.9) | .008 |
| Duration of stay (hr) (median) (IQR) | 22.0 (6.0–26.0) | 8.0 (5.0–24.0) | .010 |
| Fractures treated | n = 244 | n = 235 | |
| Procedure (m) (%) | <.001 | ||
| Bilateral | 242 (99.2) | 151 (65.1) | |
| Unilateral | 2 (0.8) | 81 (34.9) | |
| Total cement volume (mL) (median) (IQR)a | 4.6 (3.4–6.0) | 4.0 (3.0–6.0) | .053 |
| Fractures scanned by CTb | n = 214 | n = 201 | |
| Vertebral body volume (mL) (median) (IQR) | 25.7 (19.3–31.4) | 25.1 (19.4–31.9) | .74 |
| Cement volume (mL) (median) (IQR) | 5.2 (3.8–6.3) | 4.6 (2.9–6.5) | .037 |
| Cement/vertebral ratio (median) (IQR) | 0.21 (0.16–0.26) | 0.19 (0.13–0.25) | .008 |
Note:—(m) indicates numerator (No.) in category; IQR, interquartile range.
↵a For BKP, all patients were treated with HV-R bone cement (Kyphon; Medtronic Spine, Sunnyvale, California). For VP, 46 (24.3%) patients were treated with Spineplex (Stryker, Kalamazoo, Michigan); 43 (22.8%), with Parallax (ArthroCare, Austin, Texas); 34 (18.0%), with AVAtex (CareFusion, San Diego, California); 14 (7.4%), with Confidence (DePuy Spine, Raynham, Massachusetts); 11 (5.8%), with HV-R (Kyphon); 10 (5.3%), with Visioplast (Tecres, Verona, Italy); and 10 (5.3%), with Vertefix (Cook, Bloomington, Indiana). The remaining 21 (11.1%) were treated with other bone cements.
↵b CT assessments were made by the core radiographic laboratory.